---
title: "300147.SZ (300147.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300147.SZ/news.md"
symbol: "300147.SZ"
name: "300147.SZ"
parent: "https://longbridge.com/en/quote/300147.SZ.md"
datetime: "2026-05-21T15:12:47.751Z"
locales:
  - [en](https://longbridge.com/en/quote/300147.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300147.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300147.SZ/news.md)
---

# 300147.SZ (300147.SZ) — Related News

### [China's first TCR-T cell therapy product has initiated confirmatory clinical trials and is expected to be launched within two years](https://longbridge.com/en/news/286975747.md)
*2026-05-19T12:04:13.000Z*
> Xiangxue Life's TAEST16001 injection has entered the confirmatory clinical trial stage. If it progresses smoothly, it is

### [XPH Pharmaceuticals Countdown: Is it a rebirth or a quiet delisting?](https://longbridge.com/en/news/286864177.md)
*2026-05-19T06:17:50.000Z*
> XPH faces delisting risk due to continuous losses exceeding 3 billion yuan for four consecutive years. As of the first q

### [ST XPH: Elected Zhu Xueyi as the employee director of the ninth board of directors](https://longbridge.com/en/news/285834233.md)
*2026-05-10T08:15:13.000Z*
> ST XPH announced that the company will hold a staff representative meeting on April 27, 2026, to elect Zhu Xueyi as the 

### [A-share lightning rod: Shenzhen Huaqiang Shengteng's business revenue accounts for less than 0.1%, and another batch of companies are "wearing stars and hats," with Sungrow Power Supply's first-quarter revenue down 18.26% year-on-year and net profit attributable to the parent down 40.12%](https://longbridge.com/en/news/284286563.md)
*2026-04-28T00:47:20.000Z*
> The A-share market has recently seen multiple companies facing delisting risks, including Sungrow Power Supply, which re

### [XPH: Stock trading may be subject to delisting risk warning](https://longbridge.com/en/news/284240344.md)
*2026-04-27T15:06:08.000Z*
> ST XPH announced that the company expects its net assets at the end of 2025 may be negative. According to relevant regul

### [Asset impairment expands, ST XPH expects a net profit loss of 1.264 billion to 1.464 billion yuan in 2025](https://longbridge.com/en/news/283675866.md)
*2026-04-22T13:19:12.000Z*
> ST XPH expects a net profit loss of 1.264 billion to 1.464 billion yuan in 2025, with a loss of 910 million to 1.11 bill

### [XPH: The company's stock trading may be subject to delisting risk warning](https://longbridge.com/en/news/283670644.md)
*2026-04-22T12:57:54.000Z*
> ST XPH announced that during communication with Beijing Dehao International Accounting Firm regarding the progress of th

### [XPH: The pre-restructuring period has been extended to July 11, 2026](https://longbridge.com/en/news/282543030.md)
*2026-04-13T12:19:53.000Z*
> ST XPH announced that the Guangzhou Intermediate People's Court has agreed to extend the company's pre-restructuring per

### [XPH: 100% equity of Jiujibiology will be transferred to Xiangxue High-tech without compensation](https://longbridge.com/en/news/281023310.md)
*2026-03-30T12:51:27.000Z*
> Sina Finance reported on March 30th that ST XPH announced that, in order to further optimize and integrate the company's